Intravitreal Chemotherapy

Intravitreal chemotherapy is a medical procedure involving the injection of chemotherapy drugs directly into the vitreous humor of the eye. This targeted approach is primarily employed in the treatment of intraocular malignancies, such as retinoblastoma and vitreous seeds associated with advanced retinoblastoma. The vitreous humor is the gel-like substance that fills the eyeball, and delivering chemotherapy directly into this space allows for a higher concentration of the drug at the tumor site while minimizing systemic side effects. Intravitreal chemotherapy is often considered when traditional treatments, such as systemic chemotherapy or radiation therapy, are either ineffective or associated with significant adverse effects. During the procedure, a small amount of chemotherapy solution is injected into the vitreous cavity using a fine needle. The choice of chemotherapy agents and their concentrations depends on the specific type and extent of the intraocular malignancy being treated. The procedure is typically performed in a sterile environment under local anesthesia. Intravitreal chemotherapy has shown promising results in the management of retinoblastoma, particularly in cases where other treatment modalities may be challenging or less effective. However, like any medical intervention, it is not without risks and potential complications, including infection, retinal detachment, and inflammation. Therefore, the decision to pursue intravitreal chemotherapy is made on a case-by-case basis, weighing the potential benefits against the associated risks. Ongoing research and advancements in technology continue to refine the use of intravitreal chemotherapy, offering new possibilities for improving outcomes and preserving vision in patients with intraocular malignancies. As with any medical procedure, consultation with a qualified ophthalmologist or oncologist is essential to determine the most appropriate course of action based on individual circumstances